Confo Therapeutics

Confo 1
confo 1
Confo logo

Beneficial interest AvH : 6.2%

AvH contact: Jeroen Vangindertael

www.confotherapeutics.com

Confo's mission is to develop novel GPCR modulators for patients with severe and underserved diseases, with a current emphasis on rare diseases, peripheral pain and obesity.